Alterity Therapeutics Receives U.S. FDA Fast Track Designation For ATH434 To Treat Multiple System Atrophy

Alterity Therapeutics has announced that the U.S. FDA has granted Fast Track designation for ATH434 as a treatment for Multiple System Atrophy (MSA). This designation recognizes ATH434's potential to address the significant unmet need for MSA, a disease with no approved therapy. The Fast Track status will accelerate its development and review process.

David Stamler, M.D., Chief Executive Officer of Alterity, mentioned, “Receiving the FDA’s Fast Track Designation for ATH434, alongside the Orphan Drug Designation we have already received, underscores the promise of this novel agent to address the urgent need for a disease modifying therapy for individuals with MSA.”

He further explained, “This designation reinforces the potential of ATH434 as demonstrated by recent scientific findings related to its mechanism of action and the robust and clinically meaningful efficacy from our double-blind Phase 2 clinical trial. Importantly, the Fast Track designation provides us the opportunity to interact with the FDA more frequently on the advancement of ATH434, potentially accelerating its development path and approval. We look forward to leveraging the Fast Track designation to bring this promising treatment to patients as quickly as possible.”